Medincell to Participate in Two American Biotech Conferences in June 2026
Medincell announced on Tuesday that its management will participate in two major American biotech conferences in June. These presentations come as the company advances in the development of long-acting injectable treatments, with several candidates in clinical and commercial phases.
Participation in Jefferies and Evercore Conferences
Christophe Douat, CEO, and Grace Kim, Chief Strategy Officer U.S. Finance, will speak at the Jefferies Annual NY Biotech Conference, scheduled from June 2 to June 4, 2026, in New York. Their presentation is set for June 4 at 9:55 AM. The group will also be represented at the Evercore Summer Symposium, which will take place from June 22 to June 24, 2026, in Newport, Rhode Island. Investors interested in appointments during this second conference are invited to contact the organization or Medincell directly.
Portfolio of Candidates in Development
Medincell is developing treatments based on its proprietary Bepo technology, which controls the release of a drug at a therapeutic level for several days, weeks, or months through a subcutaneous or local injection of a fully bioresorbable depot. Risperidone LAI, the first treatment using this technology, received FDA approval for schizophrenia in April 2023 and for bipolar I disorder in October 2025. It is marketed in the United States by Teva under the name Uzedy. Teva submitted an application to the FDA in December 2025 for a monthly formulation of Olanzapine LAI for the treatment of schizophrenia. The FDA accepted this file on February 20, 2026.
